- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 2, 2025
Deals
Bridgebio, Revolution, Apellis/Sobi in trio of royalty agreements: Deals Report
Plus: Novartis working with Flagship-backed Profound in CV area, and more
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | Apr 17, 2023
Emerging Company Profile
Complement: taking on Apellis with a gene therapy for geographic atrophy
New target CR1 could shut down complement signaling more fully than Apellis’ C3-targeted therapy
BioCentury | Sep 21, 2021
Product Development
The non-cancer bispecific pipeline: Data Byte
Clinical bispecific programs now span four disease areas outside of cancer
BioCentury | Oct 13, 2017
Product Development
Eyeing complement data
Sorting through complement data in dry AMD
BioCentury | May 26, 2016
Product R&D
H is for cancer
How an antibody from NSCLC patients uses complement to kill cancer
BioCentury | Dec 10, 2015
Distillery Therapeutics
Therapeutics: V-set and immunoglobulin domain containing 4 (VSIG4); CD59; complement C5b-9 membrane attack complex (MAC)
Items per page:
1 - 10 of 14